Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
about
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusHealth and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.KIssues and challenges in the assessment, diagnosis and treatment of cardiovascular risk factors: assessing the needs of cardiologistsExamining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes.Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trialsOptimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63).Can costs of screening for hypertension and diabetes in dental care and follow-up in primary health care be predicted?Cost implications to health care payers of improving glucose management among adults with type 2 diabetesExubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetesMetformin and the promise of geroprotectionCost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.Metformin effects revisited.Screening for type 2 diabetes and dysglycemia.Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts.An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).[Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
P2860
Q24186667-50A52A33-2866-4413-8E95-77DD2D251CA0Q24202505-C0945C9A-4770-46A9-B69A-6515092C45E2Q24236456-A12E5DDB-5C08-4E5E-8DFA-73030067BFEDQ24797434-C5EDBEFC-C830-41A6-BAC9-AE8D18FF9DB1Q33335379-6D5D71BC-0338-4B48-B265-CF3672F9C1FEQ33506099-18C24055-23B6-4E87-A865-5E0B6C858D84Q33751401-C4347F31-6DE2-43CE-805D-1CB3D9341890Q34016162-0DAB45F5-6FEF-40A0-BCCB-E3D72AFDDBBCQ34083400-6354C8AC-4DE9-47DA-8C96-4EDF2C7B2FFDQ34113354-5F2BD596-0E1B-4A55-B8A0-1BA055EF0C89Q34158583-BF19074C-A759-4BD5-B161-5AD27B4E4506Q34317088-0A0F4276-479C-4F7B-8403-7019027CF61AQ35190998-FD0A3C29-B1A2-4AE0-B859-15F1731AB82AQ35876380-63A1D74A-A2E2-4F1D-9031-9D2F0BE3C36FQ36107738-7AC0FD67-1BAC-453D-9194-90146241C685Q36807446-C3982899-DB33-4526-AEA4-C89E38E57EBCQ37554697-5D5F381F-83C6-4CE1-B0FB-963C97D03C38Q37882225-93AD4F9B-771F-442F-BD41-5EC9F2F7AB8CQ37996073-3E5432BA-262D-449C-8943-81878338DB3AQ40513934-DEFA3ABE-FB96-4E9C-BE3B-A93446F9A8DCQ43687462-E8A5F9E5-1AD1-4F7E-A285-6F61E20A3F50Q44032471-E3C4BF93-5809-4434-9686-62B12321CBCD
P2860
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... pe II diabetes (UKPDS No. 51).
@en
Cost-effectiveness analysis of ...... patients with type II diabetes
@nl
type
label
Cost-effectiveness analysis of ...... pe II diabetes (UKPDS No. 51).
@en
Cost-effectiveness analysis of ...... patients with type II diabetes
@nl
prefLabel
Cost-effectiveness analysis of ...... pe II diabetes (UKPDS No. 51).
@en
Cost-effectiveness analysis of ...... patients with type II diabetes
@nl
P2093
P50
P921
P356
P1433
P1476
Cost-effectiveness analysis of ...... ype II diabetes (UKPDS No. 51)
@en
P2093
UKPDS Group. United Kingdom Prospective Diabetes Study
P2888
P304
P356
10.1007/S001250051617
P577
2001-03-01T00:00:00Z